Findings from University of Sassari Provide New Insights into Prostate Cancer [Resveratrol-loaded nanoparticles based on poly(epsilon-caprolactone) and poly(D,L-lactic-co-glycolic acid)-poly(ethylene glycol) blend for prostate cancer treatment]
By a News Reporter-Staff News Editor at Biotech Week -- New research on Oncology is the subject of a report. According to news reporting from Sassari, Italy, by NewsRx journalists, research stated, "Nanoencapsulation of antiproliferative and chemopreventive phytoalexin trans-resveratrol (RSV) is likely to provide protection against degradation, enhancement of bioavailability, improvement in intracellular penetration and control delivery. In this study, polymeric nanoparticles (NPs) encapsulating RSV (nano-RSV) as novel prototypes for prostate cancer (PCa) treatment were designed, characterized and evaluated using human PCa cells."
The news correspondents obtained a quote from the research from the University of Sassari, "Nanosystems, composed of a biocompatible blend of poly(epsilon-caprolactone) (PCL) and poly(d,l-lactic-co-glycolic acid)-poly(ethylene glycol) conjugate (PLGA-PEG-COOH), were prepared by a nanoprecipitation method, and characterized in terms of morphology, particle size and zeta potential, encapsulation efficiency, thermal analyses, and in vitro release studies. Cellular uptake of NPs was then evaluated in PCa cell lines DU-145, PC-3, and LNCaP using confocal fluorescence microscopy, and antiproliferative efficacy was assessed using MTT assay. With encapsulation efficiencies ranging from 74% to 98%, RSV was successfully loaded in PCL:PLGA-PEG-COOH NPs, which showed an average diameter of 150 nm. NPs were able to control the RSV release at pH 6.5 and 7.4, mimicking the acidic tumoral microenvironment and physiological conditions, respectively, with only 55% of RSV released within 7 h. In gastrointestinal simulated fluids, NPs released about 55% of RSV in the first 2 h in acidic medium, and their total RSV content within the subsequent 5 h at pH 7.4. Confocal fluorescence microscopy observations revealed that NPs were efficiently taken up by PCa cell lines. Furthermore, nano-RSV significantly improved the cytotoxicity compared to that of free RSV toward all three cell lines, at all tested concentrations (from 10 ?M to 40 ?M), proving a consistent sensitivity toward both the androgen-independent DU-145 and hormone-sensitive LNCaP cells."
According to the news reporters, the research concluded: "Our findings support the potential use of developed nanoprototypes for the controlled delivery of bioactive RSV for PCa chemoprevention/chemotherapy."
For more information on this research see: Resveratrol-loaded nanoparticles based on poly(epsilon-caprolactone) and poly(D,L-lactic-co-glycolic acid)-poly(ethylene glycol) blend for prostate cancer treatment. Molecular Pharmaceutics, 2013;10(10):3871-81. (American Chemical Society - www.acs.org; Molecular Pharmaceutics - www.pubs.acs.org/journal/mpohbp)
Our news journalists report that additional information may be obtained by contacting V. Sanna, Dept. of Chemistry and Pharmacy, Laboratory of Nanomedicine, University of Sassari , 07100 Sassari, Italy. Additional authors for this research include I.A. Siddiqui, M. Sechi and H. Mukhtar (see also Oncology).
Keywords for this news article include: Italy, Europe, Sassari, Alkenes, Oncology, Prostate Cancer, Ethylene Glycols, Prostatic Neoplasms.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC